Amphotericin B

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis, Chronic Mucocutaneous

Conditions

Candidiasis, Chronic Mucocutaneous

Trial Timeline

Sep 27, 2016 → Aug 6, 2022

About Amphotericin B

Amphotericin B is a phase 2 stage product being developed by Matinas Biopharma for Candidiasis, Chronic Mucocutaneous. The current trial status is completed. This product is registered under clinical trial identifier NCT02629419. Target conditions include Candidiasis, Chronic Mucocutaneous.

What happened to similar drugs?

5 of 20 similar drugs in Candidiasis, Chronic Mucocutaneous were approved

Approved (5) Terminated (4) Active (12)

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02629419Phase 2Completed

Competing Products

20 competing products in Candidiasis, Chronic Mucocutaneous

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
29
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Fluconazole + MicafunginAstellas PharmaApproved
35
Micafungin + CaspofunginAstellas PharmaPhase 3
40
Micafungin + FluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPhase 2
35
micafungin + caspofunginAstellas PharmaPhase 3
40
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
32
FK463Astellas PharmaPhase 2
35
Micafungin + Liposomal Amphotericin BAstellas PharmaPhase 3
40
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
36
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
36
L-743,872MerckPre-clinical
26
CaspofunginMerckPhase 2
35
L-743,872MerckPhase 2
27
Caspofungin + Amphotericin B DeoxycholateMerckPhase 2
27
Caspofungin acetate + PlaceboMerckPhase 2
27
Caspofungin + Normal SalineMerckApproved
43